No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
1 out of 7 registries used, show all original rules. |
135 |
4. Check minimum number of eventsNone |
135 |
5. Include endpointsNone |
135 |
6. Filter based on genotype QC (FinnGen only) |
116 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- Level in the ICD hierarchy
- C
- First used in FinnGen datafreeze
- DF5
Similar endpoints
↥List of similar endpoints to
Drug-induced dystonia
based on the number of shared cases.
Similar with more cases:
- Dystonia
- Extrapyramidal and movement disorders
- Neurological diseases
- Neurological diseases, wide definition
- Any operation in hilmo
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 816 | 453 | 361 |
| Only index persons | 739 | 416 | 323 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.01 | 0.01 | 0.01 |
| Only index persons | 0.01 | 0.02 | 0.01 |
| Median age at first event (years) | |||
| Whole population | 48.80 | 52.93 | 43.66 |
| Only index persons | 46.80 | 49.61 | 43.17 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 116 | 69 | 47 |
| Unadjusted period prevalence (%) | 0.02 | 0.02 | 0.02 |
| Median age at first event (years) | 47.09 | 48.94 | 44.39 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 120
- Matched controls
- 1200
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
G24.0
ICD-10 Finland
Drug-induced dystonia
+∞
173.2
120
*
112
Kela drug reimbursment
Severe psychotic and other severe mental disorders
25.7
70.5
62
48
N04AA02
ATC
biperiden; systemic
42.5
64.9
42
15
N05AH03
ATC
olanzapine; systemic
19.7
57.3
56
51
N03AE01
ATC
clonazepam; systemic
21.1
49.4
43
31
N05AX12
ATC
aripiprazole; systemic
19.7
47.7
43
33
N03AG01
ATC
valproic acid; systemic, rectal
15.4
41.2
43
42
N05AX08
ATC
risperidone; systemic
12.5
39.4
50
65
N05AH04
ATC
quetiapine; oral
10.7
39.1
75
162
F29
ICD-10 Finland
Unspecified nonorganic psychosis
16.3
37.9
37
32
N05BA01
ATC
diazepam; systemic, rectal
7.0
22.9
47
101
N05BA06
ATC
lorazepam; systemic, sublingual
10.3
21.4
27
33
Z00.4
ICD-10 Finland
General psychiatric examination, not elsewhere classified
6.9
20.5
40
81
R56.8
ICD-10 Finland
Other and unspecified convulsions
10.3
20.0
25
30
N05BA04
ATC
oxazepam; oral
5.6
19.8
63
199
G24.9
ICD-10 Finland
Dystonia, unspecified
223.5
19.1
19
*
N05AH02
ATC
clozapine; systemic
22.2
17.4
25
14
F25.9
ICD-10 Finland
Schizoaffective disorder, unspecified
41.9
17.3
21
6
N06AB04
ATC
citalopram; systemic
5.0
16.2
50
150
T36
ICD-10 Finland
Poisoning by systemic antibiotics
8.1
16.0
24
36
N05AA02
ATC
levomepromazine; systemic
14.7
15.5
26
22
N06AB03
ATC
fluoxetine; oral
5.6
15.4
36
85
N05AD01
ATC
haloperidol; systemic
17.3
15.3
24
17
P72
ICPC
Schizophrenia
18.6
15.1
23
15
F20.00
ICD-10 Finland
Paranoid schizophrenia continuous
23.7
14.3
20
10
N05CD07
ATC
temazepam; oral
6.2
14.2
28
56
N05AN01
ATC
lithium; oral
19.3
14.1
21
13
SPAT1254
SPAT
Administration of medicine
5.2
13.5
34
85
N06AX11
ATC
mirtazapine; oral
4.1
13.0
73
330
N05AB03
ATC
perphenazine; systemic, rectal
13.9
13.0
22
19
N03AX09
ATC
lamotrigine; oral
7.3
13.0
21
34
F33.10
ICD-10 Finland
Recurrent depression, moderate episode without somatic syndrome
6.7
12.5
22
39
N05AE05
ATC
lurasidone; oral
+∞
11.6
11
*
F31.7
ICD-10 Finland
Bipolar affective disorder, currently in remission
19.5
11.6
17
10
C07AA05
ATC
propranolol; systemic
3.9
11.2
48
177
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
5.5
11.0
24
52
F31.9
ICD-10 Finland
Bipolar affective disorder, unspecified
13.0
11.0
19
17
N06AB06
ATC
sertraline; oral
4.4
10.8
33
95
G24.3
ICD-10 Finland
Spasmodic torticollis
36.1
10.6
13
*
F20.30
ICD-10 Finland
Undifferentiated schizophrenia continuous
21.2
10.6
15
8
F20.9
ICD-10 Finland
Schizophrenia, unspecified
13.0
10.5
18
16
IGY01
NOMESCO Finland
Accelerated psychiatric treatment contact
11.6
10.5
19
19
N05BE01
ATC
buspirone; oral
11.6
10.5
19
19
X69
ICD-10 Finland
Intentional self-poisoning by and exposure to other and unspecified chemicals and noxious substances
9.5
10.4
21
26
IGY02
NOMESCO Finland
Psychiatric monitoring contact
10.2
10.3
20
23
J18.9
ICD-10 Finland
Pneumonia, unspecified
3.7
10.0
44
164
N06AX16
ATC
venlafaxine; oral
3.9
9.9
37
123
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
4.2
9.9
31
91
F25.10
ICD-10 Finland
Schizoaffective syndrome, depressive type with only concomitant bipolar and schizophrenic symptoms
60.0
9.8
11
*
P99
ICPC
Psychological disorders other
10.0
9.7
19
22
F31.30
ICD-10 Finland
Bipolar disorder Depressive episode without somatic syndrome
19.6
9.7
14
8
N07BB01
ATC
disulfiram; oral
9.0
9.6
20
26
N05AC02
ATC
thioridazine; oral
33.0
9.6
12
*
G24.8
ICD-10 Finland
Other dystonia
108.2
9.6
10
*
AA1AD
NOMESCO Finland
CT of head and brain
3.4
9.4
50
209
ICB01
NOMESCO Finland
Psychiatric treatment plan, standard
9.2
9.3
19
24
N05AF03
ATC
chlorprothixene; systemic
10.8
9.1
17
18
WYA30
NOMESCO Finland
Treatment of a patient needing special arrangements
4.8
9.0
23
57
ZYC01
NOMESCO Finland
Remote contact by phone
5.5
8.9
19
40
F31.5
ICD-10 Finland
Bipolar affective disorder, current episode severe depression with psychotic symptoms
54.0
8.8
10
*
F10.1
ICD-10 Finland
Mental and behavioural disorders due to use of alcohol, Harmful use
5.0
8.8
21
49
IFA01
NOMESCO Finland
Psychiatric pharmacotherapy plan, not specified
18.0
8.8
13
8
N05AL01
ATC
sulpiride; systemic
18.0
8.8
13
8
IAA01
NOMESCO Finland
Assessment of need for psychiatric treatment
8.1
8.7
19
27
N05AE04
ATC
ziprasidone; systemic
22.0
8.7
12
6
IEY05
NOMESCO Finland
Dedicated profession-specific psychiatric intervention, individual
7.5
8.6
20
31
188
Kela drug reimbursment
Psychosis requiring demanding treatment
96.6
8.5
9
*
N05CF01
ATC
zopiclone; oral
3.1
8.4
52
235
A28
ICPC
Limited function/disability NOS
3.9
8.3
29
91
N04BA02
ATC
levodopa and decarboxylase inhibitor; oral
18.8
8.3
12
7
SPAT1240
SPAT
Therapeutic discussion
4.0
8.2
27
81
G25.9
ICD-10 Finland
Extrapyramidal and movement disorder, unspecified
36.0
8.2
10
*
IGY02, ,
SPAT
24.0
8.2
11
5
A29
ICPC
General symptom/complaint other
3.7
8.1
30
98
N03AX16
ATC
[U] pregabalin
3.2
7.9
41
166
A06AD11
ATC
lactulose; oral
4.3
7.9
23
63
IGY99
NOMESCO Finland
Other psychiatric treatment contact
12.0
7.5
13
12
N39.0
ICD-10 Finland
Urinary tract infection, site not specified
3.7
7.5
28
92
F31.6
ICD-10 Finland
Bipolar affective disorder, current episode mixed
17.1
7.4
11
7
G72.8
ICD-10 Finland
Other specified myopathies
21.6
7.3
10
5
F60.30
ICD-10 Finland
Emotionally unstable personality disorder, impulsive
13.2
7.3
12
10
SPAT1222
SPAT
Counselling/guidance promoting independent living
3.7
7.2
26
83
N05BA12
ATC
alprazolam; oral
3.8
7.0
24
74
SPAT1229
SPAT
Assessment of need for aid
8.0
7.0
15
21
ICB02
NOMESCO Finland
Psychiatric treatment plan, extended/prolonged
18.0
6.9
10
6
N05AX15
ATC
cariprazine; oral
42.5
6.8
8
*
F19.1
ICD-10 Finland
Mental and behavioural disorders due to multiple drug use and use of other psychoactive substances, harmful use
42.5
6.8
8
*
F20.39
ICD-10 Finland
Undifferentiated schizophrenia UNS
42.5
6.8
8
*
F25.20
ICD-10 Finland
Schizoaffective syndrome, mixed type with only concomitant bipolar and schizophrenic symptoms
24.1
6.8
9
*
N06AX03
ATC
mianserin; oral
6.9
6.7
16
26
Z2446
NOMESCO Finland
Social worker
4.4
6.7
18
46
E11.9
ICD-10 Finland
Type 2 diabetes mellitus, without complications
3.1
6.7
34
135
P29
ICPC
Psychological sympt/compl other
3.8
6.7
23
71
T90
ICPC
Diabetes non-insulin dependent
3.0
6.6
37
156
F31.4
ICD-10 Finland
Bipolar affective disorder, current episode severe depression without psychotic symptoms
73.6
6.5
7
*
F60.31
ICD-10 Finland
Emotionally unstable personality disorder, borderline condition
19.3
6.4
9
5
110
Kela drug reimbursment
Parkinson's disease and comparable movement disrorders
19.3
6.4
9
5
N05AA01
ATC
chlorpromazine; systemic, rectal
19.3
6.4
9
5
AA400
NOMESCO Finland
Electroconvulsive therapy
28.3
6.3
8
*
F19.21
ICD-10 Finland
Addiction caused by several drugs in combination and by other psychoactive substances currently independent but staying in a controlling environment
28.3
6.3
8
*
F11.22
ICD-10 Finland
Addiction-induced dependence is currently independent but uses substitute intermittent medication
+∞
6.3
6
*
SPAT1216
SPAT
Assessment of functional ability
3.6
6.3
23
74
F41.9
ICD-10 Finland
Anxiety disorder, unspecified
3.4
6.3
26
91
ICZ03
NOMESCO Finland
Participation in compiling a psychiatric treatment plan
7.4
6.2
14
21
F31.0
ICD-10 Finland
Bipolar affective disorder, current episode hypomanic
13.5
6.2
10
8
IGV01
NOMESCO Finland
Psychiatric network contact
13.5
6.2
10
8
F39
ICD-10 Finland
Unspecified mood [affective] disorder
10.9
6.2
11
11
ZXY51
NOMESCO Finland
2-person team, doctor-nurse
10.9
6.2
11
11
R51.80
ICD-10 Finland
Headache
2.9
6.1
35
148
R02
ICPC
Shortness of breath/dyspnoea
3.5
6.0
23
76
N05AF05
ATC
zuclopenthixol; systemic
16.1
6.0
9
6
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
18
13
16.04
11.40
14.5
30.5
1513.72
1446.15
nmol/l
0.08
18
13
17
13
15.00
10.54
8.2
20.3
789.65
821.23
nmol/l
0.06
17
13
67
334
3.28
9.40
2.8
2.4
48.32
69.52
u/l
0.91
62
311
83
490
3.25
8.37
8.6
7.0
1.22
1.21
mmol/l
0.52
78
428
36
136
3.35
7.79
2.5
1.9
—
—
—
0
0
73
424
2.84
7.17
4.2
4.4
35.32
36.41
g/l
0.74
68
409
28
100
3.35
6.54
2.1
1.9
—
—
—
0
0
55
288
2.68
6.45
3.7
3.9
14.07
8.78
mg/mmol
0.26
33
179
35
146
2.97
6.29
1.8
1.4
1265.68
1225.85
nmol/l
0.09
28
115
47
231
2.70
6.21
2.6
1.9
2.97
2.74
mg/l
0.33
42
205
46
226
2.68
6.06
1.6
1.7
1.00
1.30
mg/l
0.34
34
175
28
105
3.17
6.02
2.1
1.8
—
—
—
0
0
17
46
4.14
5.88
1.6
1.5
—
—
—
0
0
73
455
2.54
5.77
2.9
2.4
73.61
74.44
nmol/l
0.07
67
409
19
59
3.64
5.44
3.1
2.2
25.89
24.06
mmol/l
1.27
19
59
18
59
3.41
4.75
1.9
1.5
—
—
—
0
0
28
122
2.69
4.54
3.8
7.1
103.29
104.43
mmol/l
0.53
28
122
10
16
6.71
4.39
1.4
1.2
—
—
—
0
0
10
16
6.71
4.39
1.4
1.2
—
—
—
0
0
43
241
2.22
3.99
5.6
3.4
1.02
1.02
kg/l
0.14
30
158
65
435
2.08
3.77
2.7
1.9
94.46
99.44
pmol/l
0.36
42
218
85
631
2.19
3.72
19.7
10.5
3.98
3.99
e9/l
0.02
79
565
98
772
2.47
3.70
4.6
4.1
11.41
9.31
mm/h
0.63
92
714
99
793
2.42
3.43
5.8
3.2
42.81
46.62
u/l
0.31
94
769
43
260
2.02
3.18
2.8
3.0
2585.37
946.17
ng/l
0.57
38
213
24
118
2.29
2.97
1.3
2.8
4.78
10.38
umol/l
0.98
18
111
13
48
2.92
2.82
3.6
2.7
0.64
0.61
%
0.08
13
48
6
10
6.25
2.73
4.2
1.0
—
—
—
0
0
6
11
5.67
2.57
1.7
1.2
586.67
220.45
mu/l
—
6
11
9
26
3.66
2.54
3.7
1.9
25.30
24.85
mmol/l
—
9
26
111
989
2.63
2.52
20.9
13.2
90.59
86.84
ml/min/173m2
0.85
99
904
115
1045
3.41
2.51
25.8
13.4
27.97
21.90
mg/l
0.95
103
841
11
38
3.08
2.49
2.8
1.8
—
—
—
0
0
27
151
2.02
2.42
3.3
2.6
1.45
2.48
e6/l
0.38
13
70
111
994
2.55
2.37
7.3
4.5
6.01
5.81
mmol/l
0.87
104
923
21
110
2.10
2.23
7.0
5.9
—
—
—
0
0
53
379
1.71
2.16
6.1
3.3
19.65
44.11
ng/l
0.99
37
238
8
25
3.35
2.13
1.3
1.3
—
—
—
0
0
9
31
3.05
2.12
1.6
1.1
—
—
—
0
0
9
31
3.05
2.12
1.6
1.1
—
—
—
0
0
42
283
1.74
2.10
3.8
2.6
0.35
0.28
e6/l
0.12
31
203
5
11
4.69
1.96
1.8
1.6
—
—
—
0
0
108
962
2.23
1.90
9.1
5.5
38.77
38.41
mmol/mol
0.17
102
908
27
166
1.81
1.82
3.4
2.5
2.03
0.90
e6/l
0.60
15
86
10
41
2.57
1.69
1.8
1.7
—
—
—
0
0
6
19
3.27
1.68
1.3
1.5
—
—
—
0
0
14
71
2.10
1.61
2.9
2.3
6.71
5.95
ug/l
—
9
63
27
172
1.74
1.61
6.1
3.8
34.50
171.87
ng/l
0.87
18
125
69
563
1.53
1.47
5.0
3.5
91.87
0.00
estimate
0.48
15
109
6
22
2.81
1.45
1.3
1.6
—
—
—
0
0
38
273
1.57
1.43
1.5
1.3
1.31
1.83
u/ml
0.23
11
76
67
561
1.44
1.15
5.1
3.5
0.00
0.00
estimate
-0.00
14
110
5
21
2.44
1.10
1.0
1.1
—
—
—
0
0
5
21
2.44
1.10
1.4
1.6
—
—
—
0
0
40
307
1.45
1.08
4.9
3.4
0.00
0.00
estimate
-0.00
12
107
67
567
1.41
1.05
5.1
3.6
0.23
0.00
estimate
0.47
13
104
5
22
2.33
1.04
1.2
1.4
—
—
—
0
0
6
27
2.28
0.95
6.2
2.3
—
—
—
0
0
6
27
2.28
0.95
5.7
1.9
—
—
—
0
0
21
145
1.54
0.93
2.4
2.3
2.32
2.39
g/l
0.20
16
133
51
419
1.38
0.92
5.6
3.3
0.00
0.01
estimate
0.49
12
94
27
198
1.47
0.91
1.4
1.3
1.17
6.95
u/ml
—
8
81
13
80
1.70
0.89
3.5
2.9
71.70
70.62
ml/min/173m2
—
7
29
11
67
1.71
0.78
2.1
6.6
27.01
25.18
mmol/l
0.95
11
67
5
23
2.22
0.77
1.4
1.5
—
—
—
0
0
5
23
2.22
0.77
1.0
1.5
—
—
—
0
0
5
24
2.13
0.75
2.6
2.2
127.00
132.94
g/l
—
5
18
5
24
2.13
0.75
1.4
1.3
9049.80
5162.60
e6/l
—
5
15
10
60
1.73
0.74
3.3
8.7
0.66
0.66
%
—
10
60
109
1032
1.61
0.74
6.7
4.8
4.42
4.70
mmol/l
2.26
103
970
10
61
1.70
0.71
3.3
8.7
1.39
1.43
%
—
10
61
5
28
1.82
0.67
1.4
1.7
—
—
—
0
0
53
456
1.29
0.66
2.0
1.9
1.67
1.41
mmol/l
0.97
47
393
12
79
1.58
0.65
1.3
1.2
9.10
181.24
u/ml
—
6
32
5
30
1.69
0.62
1.4
1.7
—
—
—
0
0
0
20
0.00
0.61
0.0
1.1
—
4.02
—
0
8
108
1030
1.49
0.58
6.5
4.8
1.34
1.47
mmol/l
3.03
101
962
9
59
1.57
0.56
1.8
1.4
—
—
—
0
0
109
1043
1.49
0.56
7.3
5.3
2.58
2.76
mmol/l
1.51
101
977
6
38
1.61
0.55
1.3
1.4
0.23
0.24
g/l
—
6
38
6
39
1.57
0.54
1.3
1.4
1.12
1.18
g/l
—
6
39
81
746
1.26
0.53
3.7
3.4
—
—
—
0
0
9
64
1.44
0.53
1.1
1.0
—
—
—
0
0
6
40
1.53
0.52
1.5
1.3
—
—
—
0
0
7
46
1.55
0.49
1.6
2.5
3.96
2.48
mg/l
—
7
33
103
982
1.35
0.48
5.8
4.0
1.51
1.27
mmol/l
2.17
94
912
20
157
1.33
0.47
2.8
2.2
10.85
13.99
umol/l
1.18
15
147
0
15
0.00
0.41
0.0
1.9
—
13.49
—
0
15
0
16
0.00
0.41
0.0
1.1
—
26.08
—
0
5
95
904
1.24
0.39
34.9
16.8
13.70
13.45
%
1.10
95
899
18
220
0.79
0.36
4.4
3.9
16.02
22.07
%
—
5
97
11
87
1.29
0.25
1.8
2.1
—
—
—
0
0
5
37
1.37
0.24
1.8
1.2
—
—
—
0
0
0
11
0.00
0.21
0.0
6.2
—
112.43
—
0
11
0
11
0.00
0.21
0.0
1.1
—
186.89
—
0
11
0
11
0.00
0.21
0.0
1.1
—
—
—
0
0
0
12
0.00
0.21
0.0
1.2
—
186.97
—
0
12
17
196
0.85
0.20
1.3
1.6
—
—
—
0
0
6
50
1.21
0.20
1.2
1.3
—
329.34
—
0
24
16
185
0.84
0.20
2.4
2.3
—
—
—
0
0
25
224
1.15
0.19
1.4
1.3
22.92
31.26
iu/ml
—
5
68
14
122
1.17
0.14
3.6
4.5
34.11
32.67
%
—
9
78
12
105
1.16
0.11
1.9
2.2
—
—
—
0
0
6
55
1.10
0.09
5.5
2.4
40.62
39.27
u/l
—
6
49
26
244
1.08
0.09
4.2
2.4
—
—
—
0
0
16
174
0.91
0.08
2.1
2.2
—
—
—
0
0
24
252
0.94
0.05
1.7
1.6
—
—
—
0
0
10
96
1.05
0.00
3.7
3.4
—
—
—
0
0
32
318
1.01
0.00
4.8
3.0
0.00
0.01
estimate
0.49
11
87
49
489
1.00
0.00
3.4
2.8
—
—
estimate
—
0
0
8
85
0.94
-0.00
3.1
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
3.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
4.9
—
773.63
—
0
8
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
5
55
0.91
-0.00
2.0
1.9
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
11.14
—
0
5
0
5
0.00
-0.00
0.0
1.2
—
33.42
—
0
5
0
6
0.00
-0.00
0.0
2.3
—
63.83
—
0
6
0
6
0.00
-0.00
0.0
3.0
—
102.67
—
0
6
0
5
0.00
-0.00
0.0
1.4
—
66.42
—
0
5
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
5
0.00
-0.00
0.0
3.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
9.13
—
0
8
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.7
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint DRUGADVERS_DYSTON and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| DRUGADVERS_DYSTON | 2.337 [1.66, 3.29] | < 0.001 |
| Birth year | 0.996 [0.99, 1.0] | 0.327 |
During the follow-up period (1.1.1998 — 31.12.2019), 94 out of 404 females with DRUGADVERS_DYSTON died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| DRUGADVERS_DYSTON | 3.612 [2.33, 5.59] | < 0.001 |
| Birth year | 0.987 [0.98, 1.0] | 0.009 |
During the follow-up period (1.1.1998 — 31.12.2019), 88 out of 311 males with DRUGADVERS_DYSTON died.
Mortality risk
Mortality risk for people of age
years, who have DRUGADVERS_DYSTON.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.25% | 0.727% |
| 5 | 1.384% | 4.207% |
| 10 | 3.357% | 10.293% |
| 15 | 6.468% | 18.763% |
| 20 | 11.315% | 30.864% |
Relationships between endpoints
↥Index endpoint: DRUGADVERS_DYSTON – Drug-induced dystonia
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data